The Cosentyx drug market has witnessed significant growth in recent years. Cosentyx is a human monoclonal antibody that inhibits the action of interleukin-17A used for the treatment of moderate to severe plaque psoriasis, psoriatic arthritis and ankylosing spondylitis. The medication has been approved across the globe for its ability to provide long-lasting relief from psoriatic joint pain and skin symptoms.
The global Cosentyx drug market is estimated to be valued at US$ 5.72 billion in 2025 and is expected to exhibit a CAGR of 7.5% over the forecast period 2025-2032.
Key Takeaways
Key players operating in the Cosentyx drug market are Novartis. Novartis has the manufacturing and marketing rights for Cosentyx worldwide. This has provided a competitive edge to Novartis in the Cosentyx drug market.
Cosentyx Drug Market Demand include increasing adoption and awareness rates of biologics due to their targeted mechanism of action and ability to provide long-lasting effects. Additionally, the market is anticipated to witness growth owing to rising incidence of psoriatic arthritis and psoriasis. According to the National Psoriasis Foundation, around 125 million people worldwide are estimated to be affected by psoriasis.
Globally, Novartis is focused on expanding its market footprint for Cosentyx across emerging regions. The company has obtained approvals across Latin America, Asia Pacific and Middle Eastern markets. It aims to enhance Cosentyx availability in high potential markets to meet the emerging treatment demand.
Market drivers
The rising prevalence of psoriasis and psoriatic arthritis globally is a major market driver. According to the National Psoriasis Foundation, psoriasis prevalence is estimated to increase by around 60% between 2010 and 2050. Additionally, Cosentyx offers several advantages over traditional systemic therapies like methotrexate including higher efficacy, convenient dosing and better safety profile. This is anticipated to drive its demand over the forecast period.
Market restraints
The high costs associated with biologics like Cosentyx pose significant affordability challenges, particularly in developing regions. Additionally, biosimilar competition after patent expiration of reference drugs can impede market growth of originator biologics. Stringent regulations for the approval of biologics also delay their market entry.
Segment Analysis
The Cosentyx Drug market is segmented into different indications such as psoriasis, psoriatic arthritis, ankylosing spondylitis etc. Among these, the psoriasis indication dominates the market with the largest share. This is because psoriasis is one of the most common autoimmune diseases affecting over 125 million people worldwide. Cosentyx drug has been very effective in treating plaque psoriasis and has replaced other biologics with much faster efficacy and better safety profile.
Global Analysis
Regionally, North America accounts for the largest share in the Cosentyx Drug market currently. This can be attributed to high adoption rates of expensive biologics and presence of major market players in countries like the US. However, Asia Pacific region is expected to witness the highest growth during the forecast period owing to rising psoriasis patient population coupled with increasing healthcare expenditure in emerging countries of China and India. In Europe, countries like Germany, UK and France contribute most to the market due to well-developed healthcare infrastructure and government support for novel therapeutics.
Get This Report in Japanese Language: コセンティクス医薬品市場
Get This Report in Korean Language: 코센텍스 의약품 시장
About Author:
Vaagisha brings over three years of expertise as a content editor in the market research domain. Originally a creative writer, she discovered her passion for editing, combining her flair for writing with a meticulous eye for detail. Her ability to craft and refine compelling content makes her an invaluable asset in delivering polished and engaging write-ups.
(LinkedIn: https://www.linkedin.com/in/vaagisha-singh-8080b91)
Comments
0 comment